• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Preclinical Trials

Nanotech derived from amniotic stem cells could help treat brain cancer

July 26, 2017 By Sarah Faulkner

Creative Medical Tech

Creative Medical Technology Holdings (OTC:CELZ) touted its exosome technology today, reporting that it demonstrated an ability to regenerate healthy brain cells while selectively halting the growth of glioma brain cancer cells in a preclinical model. The company’s exosomes are vesicles harvested from amniotic stem cell technology, which it licensed from the University of California San […]

Filed Under: Featured, Neurological, Oncology, Preclinical Trials, Stem Cells, Wall Street Beat Tagged With: creativemedicaltechnologyholdings, University of California San Diego

Study: Microneedle patch, protein combo could boost efficacy of flu vaccine

July 20, 2017 By Sarah Faulkner

Researchers at Georgia State University and Georgia Institute of Technology have devised a method to boost the efficacy of a traditional influenza vaccine. The team combined a fusion protein into a microneedle patch made from a biocompatible polymer. The patch’s needles are biodegradable, releasing vaccine into the skin as they dissolve. Mice receiving a conventional […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Preclinical Trials, Research & Development Tagged With: Georgia Institute of Technology, georgiastateuniversity

Synspira’s therapy could boost antibiotics against drug-resistant bacteria in CF patients

July 12, 2017 By Sarah Faulkner

Synspira

Privately-held Synspira touted a study today of its inhaled glycopolymer-based therapeutic with antibiotics as a potential treatment for pulmonary infection caused by the Burkholderia cepacia complex in patients with cystic fibrosis. The study was published in PLOS One. Synspira’s lead polycationic glycopolymer, SNSP113, was studied in combination with tobramycin and meropenem. These antibiotics, as well as ceftazidime, are often […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Preclinical Trials, Research & Development, Respiratory Tagged With: synspira

Capillary Biomedical takes aim at ‘the Achilles heel of diabetes’

July 7, 2017 By Sarah Faulkner

Capillary Biomedical

Major players in the medical device realm are in a heated race to develop the first artificial pancreas to help patients with diabetes manage the chronic condition. Just last year,  Medtronic (NYSE:MDT) won FDA approval for its MiniMed 670G hybrid-closed loop system. But while companies compete for the top spot in developing what could be a […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Preclinical Trials, Research & Development Tagged With: capillarybiomedical

GSK inks deal for AI-driven drug discovery

July 3, 2017 By Sarah Faulkner

Exscientia inked a drug discovery collaboration with GlaxoSmithKline (NYSE:GSK) that could bring the Scotland-based company up to $37.5 million. As a part of the deal, Exscientia plans to use its artificial-intelligence platform to discover small molecules for up to 10 disease-related targets, as chosen by GSK. GSK is slated to pay Exscientia in preclinical candidate milestone […]

Filed Under: Big Data, Featured, Pharmaceuticals, Preclinical Trials, Wall Street Beat Tagged With: exscientia, GlaxoSmithKline plc

Plant-virus nanoparticles combined with chemo delays tumor progression

June 28, 2017 By Sarah Faulkner

Case Western Reserve University

Researchers from Case Western Reserve University School of Medicine, Dartmouth Geisel School of Medicine and RWTH Aachen University have demonstrated that injecting nanoscale potato-virus particles and doxorubicin into melanoma tumors slows tumor progression in mice. The team’s work was published in Nano Letters. Although simultaneous injection of the virus particles and a chemo drug prompted a […]

Filed Under: Featured, Nanoparticles, Oncology, Preclinical Trials, Research & Development

OncoSec inks preclinical deal with Jounce Therapeutics

June 13, 2017 By Sarah Faulkner

OncoSec Medical

OncoSec Medical (NSDQ:ONCS) said today that it inked a preclinical deal with Jounce Therapeutics (NSDQ:JNCE) through the OncoSec Technology Access Program. According to the agreement, Jounce will have access to OncoSec’s gene delivery technology to assess the efficacy of intratumorally-delivered therapeutic candidates. The deal includes OncoSec’s Genesis research generator, which features customizable electroporation parameters for […]

Filed Under: Drug-Device Combinations, Featured, Preclinical Trials Tagged With: jouncetherapeutics, OncoSec Medical

Nanoparticles use 2 mechanisms to boost immunotherapy

June 12, 2017 By Sarah Faulkner

Nanoparticle immunotherapy

Cancer immunotherapy, a treatment approach that has gained momentum over the past few years, only helps a small fraction of patients. But researchers from the Johns Hopkins University School of Medicine have developed a nanoparticle that may one day help expand the patient population that benefits from immunotherapy. Immunotherapy usually falls into 1 of 2 […]

Filed Under: Featured, Immunotherapy, Nanoparticles, Oncology, Preclinical Trials, Research & Development Tagged With: Johns Hopkins

Small Utah biotech regenerates skin, hair in pigs

June 8, 2017 By Sarah Faulkner

PolarityTe

Utah-based biotech PolarityTe Inc. (NSDQ:COOL) has successfully regenerated skin and triggered hair growth in pigs with burns and abrasions. The breakthrough is a win in regenerative medicine, especially for tissue engineers hoping to help burn victims recover their skin. The firm’s approach involves using a patient’s own healthy tissue to grow human skin as a […]

Filed Under: Featured, Preclinical Trials, Regenerative Medicine, Wound Care Tagged With: polarityte

Biopolymer tested as long-acting glucose control therapy

June 6, 2017 By Sarah Faulkner

Researchers from Duke University have developed a biopolymer that could provide weeks of glucose control for patients with diabetes – in a single injection. The controlled-release treatment lasted for weeks in primates, according to a study published in Nature Biomedical Engineering. The biomedical engineers suggested that this new, injectable solution could replace daily or weekly insulin shots for […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Preclinical Trials, Research & Development Tagged With: Duke University

  • « Go to Previous Page
  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4
  • Go to page 5
  • Interim pages omitted …
  • Go to page 7
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS